Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort.

Published

Conference Paper

The objective of this study was to evaluate effects of whole body radiation exposure early in life on influenza vaccination immune responses much later in life. A total of 292 volunteers recruited from the cohort members of ongoing Adult Health Study (AHS) of Japanese atomic bomb (A-bomb) survivors completed this observational study spanning two influenza seasons (2011-2012 and 2012-2013). Peripheral blood samples were collected prior to and three weeks after vaccination. Serum hemagglutination inhibition (HAI) antibody titers were measured as well as concentrations of 25 cytokines and chemokines in culture supernatant from peripheral blood mononuclear cells, with and without in vitro stimulation with influenza vaccine. We found that influenza vaccination modestly enhanced serum HAI titers in this unique cohort of elderly subjects, with seroprotection ranging from 18 to 48% for specific antigen/season combinations. Twelve percent of subjects were seroprotected against all three vaccine antigens post-vaccination. Males were generally more likely to be seroprotected for one or more antigens post-vaccination, with no differences in vaccine responses based on age at vaccination or radiation exposure in early life. These results show that early life exposure to ionizing radiation does not prevent responses of elderly A-bomb survivors to seasonal influenza vaccine.

Full Text

Duke Authors

Cited Authors

  • Hayashi, T; Lynch, HE; Geyer, S; Yoshida, K; Furudoi, K; Sasaki, K; Morishita, Y; Nagamura, H; Maki, M; Hu, Y; Hayashi, I; Kyoizumi, S; Kusunoki, Y; Ohishi, W; Fujiwara, S; Misumi, M; Shterev, I; Nikolich-┼Żugich, J; Murasko, D; Hale, LP; Sempowski, GD; Nakachi, K

Published Date

  • October 29, 2018

Published In

Volume / Issue

  • 36 / 45

Start / End Page

  • 6650 - 6659

PubMed ID

  • 30274868

Pubmed Central ID

  • 30274868

Electronic International Standard Serial Number (EISSN)

  • 1873-2518

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2018.09.054

Conference Location

  • Netherlands